Early Multimodal Vasopressor Therapy in Clinical Trials: The Importance of Establishing a Dose Ceiling Rather Than a Dose Floor
-
By
-
Patrick M. Wieruszewski
-
Ashish K. Khanna
-
October 6, 2026
Clinical Scorecard: Early Multimodal Vasopressor Therapy in Clinical Trials: The Importance of Establishing a Dose Ceiling Rather Than a Dose Floor
At a Glance
| Category | Detail |
|---|
| Condition | Septic Shock |
| Key Mechanisms | Vasopressor therapy targeting multiple vasoconstrictor pathways. |
| Target Population | Patients presenting with septic shock. |
| Care Setting | Clinical trials evaluating vasopressor therapy. |
Key Highlights
- TRICYCLE trial established a norepinephrine equivalent (NEE) dose floor but no ceiling.
- Higher baseline NEE in TRICYCLE intervention group compared to control group.
- Mortality benefit from vasopressors diminishes as baseline NEE increases.
- Timing of vasopressor initiation is crucial for improving outcomes.
- Renin levels at baseline indicate derangement in the renin-angiotensin system.
Guideline-Based Recommendations
Diagnosis
- Identify septic shock based on clinical criteria.
Management
- Consider early initiation of multimodal vasopressor therapy.
Monitoring & Follow-up
- Monitor norepinephrine doses and timing of initiation.
Risks
- Increased mortality associated with higher baseline norepinephrine doses.
Patient & Prescribing Data
Patients with septic shock requiring vasopressor support.
Early treatment initiation and lower doses may improve outcomes.
Clinical Best Practices
- Define a ceiling for qualifying vasopressor doses in trials.
- Constrain the interval between reaching pressor threshold and randomization.
- Document both pressor dose and elapsed time for each agent initiation.
Related Resources & Content
